List of Tables
Table 1. Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Competitive Situation by Manufacturers in 2025
Table 4. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Drugs for Transthyretin Amyloid Cardiomyopathy Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Drugs for Transthyretin Amyloid Cardiomyopathy, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Drugs for Transthyretin Amyloid Cardiomyopathy, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Drugs for Transthyretin Amyloid Cardiomyopathy, Product Types and Applications
Table 12. Global Key Manufacturers of Drugs for Transthyretin Amyloid Cardiomyopathy, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Drugs for Transthyretin Amyloid Cardiomyopathy Companies by Tier (Tier 1, Tier 2, Tier 3), based on Drugs for Transthyretin Amyloid Cardiomyopathy Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region (K Units), 2021–2026
Table 18. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Region (2021–2026)
Table 19. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region (K Units), 2027–2032
Table 20. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Region (2027–2032)
Table 21. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Region (US$ Million), 2021–2026
Table 22. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Region (2021–2026)
Table 23. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Region (US$ Million), 2027–2032
Table 24. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Region (2027–2032)
Table 25. North America Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (K Units), 2021–2026
Table 27. North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (K Units), 2027–2032
Table 28. North America Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Country (US$ Million), 2021–2026
Table 29. North America Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (K Units), 2021–2026
Table 32. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (K Units), 2027–2032
Table 33. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (K Units), 2021–2026
Table 42. Latin America Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (K Units), 2027–2032
Table 43. Latin America Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Country (US$ Million), 2027–2032
Table 50. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units) by Type (2021–2026)
Table 51. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units) by Type (2027–2032)
Table 52. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Type (2021–2026)
Table 53. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Type (2027–2032)
Table 54. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Type (2021–2026)
Table 57. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Type (2027–2032)
Table 58. Global Drugs for Transthyretin Amyloid Cardiomyopathy Price (US$/Unit) by Type (2021–2026)
Table 59. Global Drugs for Transthyretin Amyloid Cardiomyopathy Price (US$/Unit) by Type (2027–2032)
Table 60. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units) by Application (2021–2026)
Table 61. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units) by Application (2027–2032)
Table 62. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Application (2021–2026)
Table 63. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Application (2027–2032)
Table 64. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Application (2021–2026)
Table 67. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Application (2027–2032)
Table 68. Global Drugs for Transthyretin Amyloid Cardiomyopathy Price (US$/Unit) by Application (2021–2026)
Table 69. Global Drugs for Transthyretin Amyloid Cardiomyopathy Price (US$/Unit) by Application (2027–2032)
Table 70. Pfizer Company Information
Table 71. Pfizer Description and Business Overview
Table 72. Pfizer Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Pfizer Drugs for Transthyretin Amyloid Cardiomyopathy Product
Table 74. Pfizer Recent Developments/Updates
Table 75. Teva Company Information
Table 76. Teva Description and Business Overview
Table 77. Teva Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Teva Drugs for Transthyretin Amyloid Cardiomyopathy Product
Table 79. Teva Recent Developments/Updates
Table 80. Avet Pharmaceuticals Company Information
Table 81. Avet Pharmaceuticals Description and Business Overview
Table 82. Avet Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Avet Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Product
Table 84. Avet Pharmaceuticals Recent Developments/Updates
Table 85. Zydus Pharms Company Information
Table 86. Zydus Pharms Description and Business Overview
Table 87. Zydus Pharms Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Zydus Pharms Drugs for Transthyretin Amyloid Cardiomyopathy Product
Table 89. Zydus Pharms Recent Developments/Updates
Table 90. Alnylam Pharmaceuticals Company Information
Table 91. Alnylam Pharmaceuticals Description and Business Overview
Table 92. Alnylam Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Alnylam Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Product
Table 94. Alnylam Pharmaceuticals Recent Developments/Updates
Table 95. Akcea Therapeutics Company Information
Table 96. Akcea Therapeutics Description and Business Overview
Table 97. Akcea Therapeutics Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Akcea Therapeutics Drugs for Transthyretin Amyloid Cardiomyopathy Product
Table 99. Akcea Therapeutics Recent Developments/Updates
Table 100. Ionis Pharmaceuticals Company Information
Table 101. Ionis Pharmaceuticals Description and Business Overview
Table 102. Ionis Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Ionis Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Product
Table 104. Ionis Pharmaceuticals Recent Developments/Updates
Table 105. Qilu pharmaceutical Company Information
Table 106. Qilu pharmaceutical Description and Business Overview
Table 107. Qilu pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Qilu pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product
Table 109. Qilu pharmaceutical Recent Developments/Updates
Table 110. Chia Tai Tianqing Pharmaceutical Company Information
Table 111. Chia Tai Tianqing Pharmaceutical Description and Business Overview
Table 112. Chia Tai Tianqing Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Chia Tai Tianqing Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product
Table 114. Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
Table 115. Luoxin Pharmaceutical Company Information
Table 116. Luoxin Pharmaceutical Description and Business Overview
Table 117. Luoxin Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Luoxin Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product
Table 119. Luoxin Pharmaceutical Recent Developments/Updates
Table 120. Zhengzhou Taifeng Pharmaceutical Company Information
Table 121. Zhengzhou Taifeng Pharmaceutical Description and Business Overview
Table 122. Zhengzhou Taifeng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Zhengzhou Taifeng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product
Table 124. Zhengzhou Taifeng Pharmaceutical Recent Developments/Updates
Table 125. Shapuaisi Pharma Company Information
Table 126. Shapuaisi Pharma Description and Business Overview
Table 127. Shapuaisi Pharma Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Shapuaisi Pharma Drugs for Transthyretin Amyloid Cardiomyopathy Product
Table 129. Shapuaisi Pharma Recent Developments/Updates
Table 130. Tonghua Zhongsheng Pharmaceutical Company Information
Table 131. Tonghua Zhongsheng Pharmaceutical Description and Business Overview
Table 132. Tonghua Zhongsheng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Tonghua Zhongsheng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product
Table 134. Tonghua Zhongsheng Pharmaceutical Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Drugs for Transthyretin Amyloid Cardiomyopathy Distributors List
Table 138. Drugs for Transthyretin Amyloid Cardiomyopathy Customers List
Table 139. Drugs for Transthyretin Amyloid Cardiomyopathy Market Trends
Table 140. Drugs for Transthyretin Amyloid Cardiomyopathy Market Drivers
Table 141. Drugs for Transthyretin Amyloid Cardiomyopathy Market Challenges
Table 142. Drugs for Transthyretin Amyloid Cardiomyopathy Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report
List of Figures
Figure 1. Product Picture of Drugs for Transthyretin Amyloid Cardiomyopathy
Figure 2. Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Share by Type: 2025 & 2032
Figure 4. Transthyretin Tetramer Stabilizer Product Picture
Figure 5. RNA Interference Product Picture
Figure 6. Antisense Oligonucleotides Product Picture
Figure 7. Other Product Picture
Figure 8. Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Value by Application (US$ Million), 2021–2032
Figure 9. Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Share by Application: 2025 & 2032
Figure 10. Hospital and Clinic
Figure 11. Retail Pharmacies
Figure 12. Other
Figure 13. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Size (US$ Million), 2021–2032
Figure 15. Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales (K Units), 2021–2032
Figure 16. Global Drugs for Transthyretin Amyloid Cardiomyopathy Average Price (US$/Unit), 2021–2032
Figure 17. Drugs for Transthyretin Amyloid Cardiomyopathy Report Years Considered
Figure 18. Drugs for Transthyretin Amyloid Cardiomyopathy Sales Share by Manufacturers in 2025
Figure 19. Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Share by Manufacturers in 2025
Figure 20. Top 5 and Top 10 Global Drugs for Transthyretin Amyloid Cardiomyopathy Players: Market Share by Revenue in Drugs for Transthyretin Amyloid Cardiomyopathy in 2025
Figure 21. Drugs for Transthyretin Amyloid Cardiomyopathy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 22. Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 23. North America Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Country (2021–2032)
Figure 24. North America Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Country (2021–2032)
Figure 25. United States Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Canada Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Country (2021–2032)
Figure 28. Europe Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Country (2021–2032)
Figure 29. Germany Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. France Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. U.K. Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Italy Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Russia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Asia Pacific Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Region (2021–2032)
Figure 35. Asia Pacific Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Region (2021–2032)
Figure 36. China Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Japan Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. South Korea Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. India Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Australia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. China Taiwan Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Southeast Asia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Latin America Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Country (2021–2032)
Figure 44. Latin America Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Country (2021–2032)
Figure 45. Mexico Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Brazil Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Argentina Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Colombia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Middle East and Africa Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Country (2021–2032)
Figure 50. Middle East and Africa Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Country (2021–2032)
Figure 51. Turkey Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Saudi Arabia Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. UAE Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Global Sales Market Share of Drugs for Transthyretin Amyloid Cardiomyopathy by Type (2021–2032)
Figure 55. Global Revenue Market Share of Drugs for Transthyretin Amyloid Cardiomyopathy by Type (2021–2032)
Figure 56. Global Drugs for Transthyretin Amyloid Cardiomyopathy Price (US$/Unit) by Type (2021–2032)
Figure 57. Global Sales Market Share of Drugs for Transthyretin Amyloid Cardiomyopathy by Application (2021–2032)
Figure 58. Global Revenue Market Share of Drugs for Transthyretin Amyloid Cardiomyopathy by Application (2021–2032)
Figure 59. Global Drugs for Transthyretin Amyloid Cardiomyopathy Price (US$/Unit) by Application (2021–2032)
Figure 60. Drugs for Transthyretin Amyloid Cardiomyopathy Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
